Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes trial Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study | Diabetes Therapy orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes trial Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study | Diabetes Therapy ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes trial Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study | Diabetes Therapy, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes trial Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study | Diabetes Therapy in your area.
Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme - Thethi - 2020 - Diabetes, Obesity and Metabolism
27.81
NEJM Editorial Fellow Harleen Marwah, MD, summarizes the SOUL trial. Read the full trial results at NEJM.org (link in bio). , , #ACC25 #Cardiology #ClinicalTrials #NEJM
29.33
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
21.39
Results of SOUL Trial with Oral Semaglutide
29.58
An oral formulation of semaglutide lowered the risk major adverse cardiovascular events by 14% in four years, with no change in safety profile compared to placebo, according to the SOUL study. #ACC25
22.19
At ADA 2025, the SOUL trial revealed that oral semaglutide (Rybelsus) reduced the risk of major cardiovascular events—like heart attack, stroke, and CV death—by 14% over ~4 years in type 2 diabetes
24.32
Full article: Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients
24.25
